The international surgical journal with global reach

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406.

Published: 22nd March 2019

Authors: Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul J-L et al.

Conclusion

Some 593 patients were followed for a median of 33.6 months. Disease-free survival was improved with FOLFIRINOX (21.6 months) compared to gemcitabine (12.8 months; P=0<0.001).Overall 3-year survival rates were 63.4 and 48.6 per cent, respectively.

Pubmed Link